MarketCap
Facebook
X
TelegramGeschäftsbericht 2024
hinzugefügt 21.03.2026
Can-Fite BioPharma Ltd. EV/EBITDA 2011-2026 | CANF
EV/EBITDA Jährlich Can-Fite BioPharma Ltd.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -43.1 | -1.08 | -19.2 | 105 | 243 | 109 | 146 | 34.2 | -3.25 | -4.2 | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 243 | -43.1 | 56.5 |
EV/EBITDA anderer Aktien in der Pharmaeinzelhändler
| Name | EV/EBITDA | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-0.591 | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-0.994 | $ 3.6 | 1.34 % | $ 8.66 B |  Australia |
 |
Aytu BioScience
AYTU
|
-1.92 | $ 2.66 | - | $ 16.7 M |  USA |
 |
BioNTech SE
BNTX
|
4.1 | $ 91.28 | - | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
595 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
10.7 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
4.22 K | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M | France |
 |
Cerus Corporation
CERS
|
-24.7 | $ 1.85 | - | $ 353 M | USA |
 |
Midatech Pharma plc
MTP
|
0.796 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.42 | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
0.777 | - | -24.86 % | $ 820 K | USA |
 |
Coherus BioSciences
CHRS
|
-4.11 | $ 1.67 | - | $ 196 M | USA |
 |
Celldex Therapeutics
CLDX
|
0.185 | $ 31.37 | - | $ 2.08 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
190 | $ 0.44 | - | $ 5.04 M |  Israel |
 |
Advaxis
ADXS
|
-82.4 | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.32 | - | - | $ 86.2 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
0.205 | $ 2.32 | - | $ 1.03 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
14 | - | - | - |  Russia |
 |
Catalyst Pharmaceuticals
CPRX
|
7.16 | $ 24.98 | - | $ 3.05 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-0.248 | $ 10.14 | - | $ 135 M | USA |
 |
Cardiff Oncology
CRDF
|
-8.15 | $ 1.58 | - | $ 106 M | USA |
 |
Curis
CRIS
|
-7.31 | $ 0.53 | - | $ 6.98 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-8.38 | $ 37.7 | - | $ 3.55 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
13.1 | $ 49.15 | - | $ 4.42 B |  Schweiz |
 |
Aeterna Zentaris
AEZS
|
4.4 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-1.85 | - | -10.17 % | $ 12.2 K | USA |
 |
CytomX Therapeutics
CTMX
|
-3.71 | $ 4.4 | - | $ 607 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-2.05 | $ 0.86 | - | $ 5.79 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-4.27 | - | - | $ 1.01 B | USA |
 |
Cue Biopharma
CUE
|
-7.01 | $ 0.18 | - | $ 17.1 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.546 | - | - | $ 26.5 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-0.266 | $ 20.36 | - | $ 2.84 B | France |
 |
AIkido Pharma
AIKI
|
-45.5 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
388 | - | -45.71 % | $ 1.2 M | Canada |
 |
Denali Therapeutics
DNLI
|
-14.1 | $ 19.38 | - | $ 3.19 B | USA |
 |
Dyadic International
DYAI
|
-6.69 | $ 0.87 | -2.8 % | $ 31.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-4.64 | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-7.74 | - | - | $ 867 M | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
-249 | $ 3.54 | - | $ 238 B | Britain |
 |
Akouos
AKUS
|
-1.13 | - | 0.23 % | $ 488 M | USA |
 |
Entera Bio Ltd.
ENTX
|
-1.68 | $ 1.19 | - | $ 55.5 M | Israel |
 |
Equillium
EQ
|
-1.46 | $ 2.01 | - | $ 115 M | USA |
 |
Allakos
ALLK
|
-1.56 | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
0.298 | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
-31.5 | $ 330.34 | - | $ 43.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-5.5 | - | - | $ 2.17 B | USA |
 |
Fate Therapeutics
FATE
|
-25.4 | $ 1.19 | - | $ 141 M | USA |
 |
Aileron Therapeutics
ALRN
|
-0.0369 | - | 10.36 % | $ 9.8 M | USA |